MONTREAL, June 1, 2022
/CNW/ - Lumiera Health Inc. (TSXV: NHP) (the
"Company" or "Lumiera "), a company specializing
in the development and commercialization of natural health
products, is pleased to provide an update to announce that the
corporate strategy and plans that were put place in 2021, are
continuing to prove successful with Lumiera's fiscal Q2'22 being
another strong quarter with sales +28% vs Q2 2021.
The increase in the Company's sales has been driven by increased
retail and online distribution which has led to trial and repeat
purchases of Awaye™ natural pain relief cream and Bazzzics™, a
natural non-addictive sleep aid.
"We continue to receive outstanding feedback from Awaye™ and
Bazzzics™ users. This positive feedback and the continued growth
validates our strategies and plans. We have been expanding
availability and distribution across Canada. We are very
pleased with the performance of our Team and Partners in
British Columbia and we look
forward to replicating that success in Ontario and the Northeast US."
says Simon Castonguay, Interim CFO
of Lumiera "We will continue to invest in distribution expansion,
trial and allocate more cash to inventory to enable us to
capitalize on additional growth opportunities.".
Q2 financial statements will be released on or before
July 29, 2022.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking
information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2021,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
Related Links: www.lumiera.ca
SOURCE Lumiera Health Inc.